Dapagliflozin Promising as Add-On Therapy in Young People Wi
A placebo-controlled, randomized, phase-3 trial of dapagliflozin added to metformin, insulin or both in young people aged 10 to 24 years (mean age, 16.1 years) with type 2 diabetes and HbA1c between 6.5% and 11%.

Thirty-nine participants were randomly allocated to add dapagliflozin 10 mg once daily and 33 to matching placebo during a 24-week double-blind period, which was followed by a 28-week open-label safety extension in which all 72 participants received dapagliflozin.

The addition of dapagliflozin did not lead to a significant difference in HbA1c concentration versus placebo at 24 weeks in the intention-to-treat analysis (mean change in HbA1c, -0.25% vs. 0.50%; P=0.10). However, a prespecified analysis of protocol-compliant participants showed a statistically significant decrease in HbA1c with add-on dapagliflozin versus placebo (mean change, -0.51% vs. 0.62%; P=0.012).

Dapagliflozin can help children, adolescents and young adults with type 2 diabetes improve their hemoglobin A1c levels when added to other anti-diabetes therapies.

Source: https://www.medscape.com/viewarticle/972292